

NUPR1 INHIBITION FOR TREATING CANCER

Use of NUPR1 inhibitors as drugs, in particular as anti-cancer drugs.

Description

Cancer is a major burden of disease worldwide. Each year, tens of millions of people are diagnosed with cancer around the world, and more than half of the patients eventually die from it. Globally, nearly 1 in 6 deaths is due to cancer.

In spite of the recent advances, there remains a need in the art for novel anti-cancer drugs either as simple alternatives to already available drugs or having better properties than the drugs already available. These better properties can have a more effective activity against tumors and/or a smaller or absent risk of developing unwanted side effects.

There also remains a need for anti-cancer compounds having no side effects at an effective dose when used in a patient in need thereof. In particular, there remains a need for anti-cancer compounds having no neurological side effects at an effective dose when used in a patient in need thereof.

Considering the in vitro and in vivo experimental evidence provided in the present text, the inventors consider that tumors, and in particular cancers selected from the group consisting of pancreatic cancer, liver cancer, melanoma, colon cancer, glioblastoma, osteosarcoma, prostate cancer and breast cancer, and more particularly pancreatic cancer, can be treated through the use of at least a compound of formula of the invention, administered alone or in combination with other anti-cancer active agents.

Innovative Aspects

The use of the family of the invention compounds presents the following advantages over other compounds with similar anti-cancer activity:

- Producing at least same anti-cancer effect.
- Presenting less or no neurological side effects.



IPR Status

European Patent Application (2018) and international patent application (PCT, 2019) with extensión possibilities.

Available for

Agreements for further research or development.

Exclusive/non-exclusive licence agreement

Contact

Institute for Health Research Aragón

Innovation Unit:

innovacion@iisaragon.es